AMENDMENTS TO THE CLAIMS

1. **(Canc lled)**

2. **(Previously Presented)** A method for treatment of HBV or HIV infections comprising administering to an individual in need thereof an effective amount of the compound of formula IId'



IId'

wherein R_2 is the residue of an aliphatic L-amino acid, p is 0, 1 or 2-20, and q is 0, or a pharmaceutically acceptable salt thereof.

3. **(Cancelled)**

4. **(Currently Amended)** The method according to claim 2, wherein R_2 ~~defines an~~ is the residue of isoleucine or ~~a~~ valine ~~derivative~~ in said compound.

5. **(Original)** The method according to claim 4, wherein said compound is selected from the group consisting of

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-butyryl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-hexanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-octanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-decanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-dodecanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-myristoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-palmitoyl] guanosine,

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-stearoyl] guanosin ,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-docosanoyl] guanosin ,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-eicosanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-butyryl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-hexanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-octanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-decanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-dodecanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-myristoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-palmitoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-stearoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-docosanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-butyryl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-eicosanoyl] guanosine and pharmaceutically acceptable salts thereof.

6. **(Previously Presented)** The method according to claim 2, wherein p is 0 in said compound.

7. **(Currently Amended)** The method according to claim 6, wherein said compound is denoted 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-propionyl] guanosine; or 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-propionyl] guanosine, wherein the propionyl moiety ~~defines an~~ has the configuration of L-lactic acid ~~derivative~~, and pharmaceutically acceptable salts thereof.

8. **(Currently Amended)** The method according to claim 6, wherein said compound is denoted 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-propionyl] guanosine, wherein the propionyl moiety ~~defines an~~has the configuration of L-lactic acid ~~derivative~~, and pharmaceutically acceptable salts thereof.

9. **(Canc ll d)**

10. **(Cancelled)**

11. **(Previously Presented)** The method of claim 2, wherein said compound is administered in an amount of 50 to 1,500 mg.

12. **(Previously Presented)** The method of claim 2, wherein said compound is administered in an amount of 100 to 700 mg.

13. **(Previously Presented)** The method of claim 2, wherein said compound is administered once, twice or three times per day.

14. **(Cancelled)**

15. **(Original)** The method of claim 14, wherein said blood serum level of said active metabolite is 0.01 to 100 µg/ml.

16. **(Original)** The method of claim 14, wherein said blood serum level of said active metabolite is 0.1 to 5 µg/ml.

17. **(Previously Presented)** The method of claim 2, wherein the retroviral infection is HIV.

18. **(Previously Presented)** The method of claim 8, wherein the retroviral infection is HIV.